Ligand Pharmaceuticals. has filed a patent for nucleotide prodrug compounds to treat viral infections. The compounds of Formula I, II, and III are disclosed in the claim. GlobalData’s report on Ligand Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Ligand Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Ligand Pharmaceuticals's grant share as of January 2024 was 42%. Grant share is based on the ratio of number of grants to total number of patents.
The patent application (Publication Number: US20230391807A1) discloses a series of compounds represented by Formula I, II, and III, with specific variations outlined in the subsequent claims. These compounds are designed for use in treating viral infections, with the potential to be part of pharmaceutical compositions alongside other therapeutic agents. The patent also covers the method of administering these compounds to subjects in need of treatment, particularly focusing on mammals, including humans.
The claims within the patent application highlight the specific structural and functional characteristics of the compounds, emphasizing their potential utility in combating viral infections. By detailing the variations in substituents and alkyl groups, the patent provides a clear framework for the development and application of these compounds in pharmaceutical compositions. The focus on treating viral infections, particularly in mammals such as humans, underscores the potential significance of these compounds in addressing critical healthcare needs. Overall, the patent application offers a comprehensive overview of the compounds' properties, their intended use in medical treatment, and the method of administration to achieve therapeutic benefits, particularly in the context of viral infections.
To know more about GlobalData’s detailed insights on Ligand Pharmaceuticals, buy the report here.
See Also:
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
